Mesothelioma Justice

Actos Attorneys: The exact mechanism(s) of BCG is still not fully understood. It is known BCG actually attaches to and enters cancer cells. BCG is thought to trigger an increased immune reaction in the bladder, thereby killing off cancer cells. BCG is held in the bladder for two hours. One should not hold it longer as adverse reactions are increased. The individual should then void into a toilet at home, preferably in a seated position to avoid splashing. After voiding, the toilet is disinfected with bleach. Since BCG can be shed from the urethra after treatment for several days, condoms should be used or one should abstain from sexual relations for at least 48 hours after treatment.

Studies have shown an approximately 40% reduction in tumor recurrence in those treated with BCG as compared with those without treatment.For those with CIS, the reduction is even greater at approximately 70%. For individuals with residual tumors after resection, complete response is generally about 60%.Despite intravesical therapy, ultimately between 10-20% of individuals with superficial bladder cancer will develop muscle invasive disease.

After a 6 week induction course of weekly BCG, treatment is often repeated with 3 weekly treatments at 3 months, 6 months and then every 6 months for up to 3 years. This regimen was shown to decrease recurrences and increase complete responses as compared to induction treatment alone. Unfortunately, despite initial success, over long periods of time, many will experience disease recurrence and progression.Treatment regimens can be individualized based on the patient’s progress and his adverse reactions to treatment, which generally increase with repeated cycles.

For more information on Actos Attorneys follow us on our RSS Feeds.

Adverse reactions are side effects of treatment. Approximately 95% of individuals will tolerate treatments well. Adverse reactions may be mild. Common reactions include cystitis (inflammation of the bladder characterized by burning on urination), hematuria, mild fever, malaise, and nausea. These symptoms generally pass without any treatment. For bothersome symptoms, various medications may prove helpful. Your physician can prescribe medication for burning or urinary frequency. For those with persistent cystitis, antibiotics can be utilized. For individuals experiencing severe symptoms lasting more than 48 hours, isoniazid, an anti-tuberculous drug can be prescribed. A short course of 3 days, starting the day before the next dose of BCG can be used to prevent severe side effects. Fortunately severe reactions resulting in sepsis, a life threatening condition characterized by high fever, chills and drop in blood pressure, is exceedingly rare. Sepsis would be treated in a hospital with triple anti-tuberculous drugs, steroids, and broad spectrum antibiotics.

Information from other sources on Actos Attorneys

As treatment cycles progress, generally adverse reactions increase in severity, the most common being cystitis. Patients should not receive additional doses until they are asymptomatic. Studies have demonstrated increasing the intervals between treatments and reducing the dose of the BCG can still result in perhaps equal efficacy, but with reduced toxicity. BCG therapy results in marked inflammation of the bladder wall. Cystoscopy done too soon after therapy would reveal a markedly reddened surface, making finding a bladder tumor difficult. Furthermore, microscopically, there will be severe reactive changes, complicating the pathologist’s job, as deciding between changes from the BCG and recurrent cancer, would be extremely difficult.

Recurrence of bladder cancer after the initial induction course, or relapse after complete response, would indicate failure of therapy. When two or more courses result in recurrence or when recurrence develops during the first six to twelve months after induction and maintenance therapy, patients generally are felt to have disease which is at higher risk for progression. A high percentage of patients who are complete responders remain tumor free for up to five years. However, with the passage of more time, additional patients will have late recurrences. For those with late recurrences (two to three years after therapy), most will respond to repeat BCG therapy.

Our use of the term or terms Actos Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Attorneys visit our site often.

Actos Attorneys

Actos Attorneys: When an individual has diffuse, high grade cancer of the bladder, even when superficial, bladder removal may be warranted. Many may have widespread carcinoma in situ (CIS) in conjunction with papillary disease. One can expect a high rate of recurrence and a high rate of progression to invasive disease. Generally, intravesical therapy is tried first. If this therapy is unsuccessful, repeated therapy or alternate intravesical therapies can be tried. However, with failure of intravesical therapy, further trials may prove to be equally ineffective and lead to unnecessary delay for potentially definitive curative therapy. Many recommend removal of the bladder if two courses of six weeks of BCG are ineffective. Therefore, radical cystectomy is a treatment option for any individual who is thought to be at significant risk for progression to musclc invasive and potentially metastatic disease.

For individuals with recurrent disease despite tumor removal and intravesical therapy, progression to a more serious, muscle invasive disease is common. The patient at high risk for progression must consider radical cystectomy. If the individual is not a candidate for radical cystectomy because of poor health or the individual refuses cystectomy, radiation therapy can be considered. There are no good studies available and it is difficult to assess the efficacy of radiation alone since it is always combined with TURBT and the completeness of tumor resection is an uncertain variable. In general, radiation plays a minimal role in the treatment of superficial bladder cancer.

For more information on Actos Attorneys follow us on our RSS Feeds.

For those individuals whose bladder tumors are at high risk for recurrence or progression, instillation of agents directly into the bladder can be worthwhile. The forms of therapeutic agents come in two groups: chemotherapy or immunotherapy. It is fortunate the bladder is readily accessible to these agents, allowing for direct action with minimal systemic side effects.

Those individuals at high risk for recurrence and or progression should be considered for this therapy. Individuals with multiple or diffuse superficial tumors, large tumors, high grade tumors, superficially invasive tumors, those with recurrence within one year, or individuals with CIS all should be considered for this treatment. In addition, those with positive cytology after resection or patients with persistent superficial tumors which could not be removed should also be considered.

Information from other sources on Actos Attorneys

The agent is passed via a catheter into the bladder. The passage of the catheter generally takes just a few seconds in a woman, and perhaps ten seconds in a man. The urethral meatus (the outermost part of the urethra) is first cleansed with an antiseptic solution and then the catheter, which is made slippery with a sterile lubricant, is inserted up the urethra and into the bladder. On passage of the catheter, there is minor, short lived discomfort which may be reduced by an injection up the urethra with numbing medication. The various therapeutic agents are not painful during the infusion but may cause side effects afterwards. Depending on the agent instilled, the patient is asked not to void for a period of time afterwards to allow the agent to have its maximal effect on the bladder lining.

BCG is a living but attenuated form of tuberculosis bacteria. Similar to other living vaccines, it is used to create a heightened immunity. There are a number of precautions which must be taken to make sure the BCG is infused safely. BCG should not be infused immediately or shortly after tumor resection. Several weeks should be allowed to pass so the BCG does not gain access into open blood vessels. In addition, BCG should not be infused if the individual has a urinary infection, has active bleeding, or if the catheterization is traumatic and causes bleeding. It should not be used in patients whose immune system is seriously compromised or for those on steroids, which can decrease the immune system.

Our use of the term or terms Actos Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Attorneys visit our site often.

Actos Attorneys

Actos Attorneys 12/15/2011: The American Cancer Society estimates that in 2006,61,420 new cases of bladder cancer were diagnosed in the United States with approximately 73% of those occurring in men. In the same year, this cancer caused approximately 13,060 deaths with approximately two out of three of those being in men. The disease is more common in whites than blacks. The incidence of bladder cancer increases with age in both sexes. When bladder cancer occurs in young people, it tends to grow slower and not be as serious. In men, it is the fourth most common cancer. However, because of the rate of recurrences and long term survival, it is the second most prevalent cancer in middle aged and elderly men. In women, it is the eighth most common cancer. The average age at diagnosis is 65. Over the past decade, there has been both an increased incidence, but also an increased rate of survival for bladder cancer.

For more information on Actos Attorneys follow us on our RSS Feeds.

Our use of the Terms Actos Lawyers , Actos Litigation is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have

any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com